World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
59200
World Ranking
9847
National Ranking
5062

Pinuccia Valagussa publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pinuccia Valagussa sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 356 publications — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pinuccia Valagussa D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pinuccia Valagussa sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Pinuccia Valagussa is affiliated with the University of Louisville in the United States. Their research encompasses a broad spectrum of topics primarily within medicine, with specific focus on oncology and cancer-related studies. Over their career, they have contributed to the advancement of knowledge in several interconnected fields including biochemistry, genetics, molecular biology, pulmonary and respiratory medicine, and cancer research.

The scientist's work is concentrated in the study of cancer immunotherapy and biomarkers, HER2/EGFR in cancer research, and breast cancer treatment studies. Additional topics of research cover cancer genomics and diagnostics, advanced breast cancer therapies, monoclonal and polyclonal antibodies research, as well as cancer treatment and pharmacology.

Valagussa's publication record includes frequent contributions to respected journals and venues such as:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Zenodo (CERN European Organization for Nuclear Research)
  • The Lancet Oncology

They have co-authored several papers with notable frequent collaborators including Luca Gianni, Giampaolo Bianchini, Giuseppe Viale, Lucia Del Mastro, and Marc Thill.

Some of their recent publications include the following papers:

  • "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study", published in 2022 in Annals of Oncology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials", published in 2021 in The Lancet Oncology
  • "Spatial predictors of immunotherapy response in triple-negative breast cancer", published in 2023 in Nature
  • "Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study", published in 2020 in Cancer Research
  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials", published in 2023 in The Lancet

Their scholarly contributions have addressed multiple aspects of breast cancer therapies, treatment efficacy, and immunotherapy response predictors, reflecting a consistent thematic engagement with oncology-focused research.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

    Bonadonna G;Brusamolino E;Valagussa P;Rossi A

  • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Alexey Manikhas

  • Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

    Gianni Bonadonna;Pinuccia Valagussa;Angela Moliterni;Milvia Zambetti

  • Dose-response effect of adjuvant chemotherapy in breast cancer.

    Gianni Bonadonna;Pinuccia Valagussa

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

  • Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More

    Gianni Bonadonna;Umberto Veronesi;Cristina Brambilla;Laura Ferrari

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

    Gianni Bonadonna;Pinuccia Valagussa;Cristina Brambilla;Laura Ferrari

  • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

    Luca Gianni;Milvia Zambetti;Kim Clark;Joffre Baker

  • High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

    Gianni Am;Bregni M;Siena S;Brambilla C

  • Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients.

    Pinuccia Valagussa;Gianni Bonadonna;Umberto Veronesi

  • Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Ana Lluch

  • Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

    Gianni Bonadonna;Milvia Zambetti;Pinuccia Valagussa

  • ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

    Simonetta Viviani;Pier Luigi Zinzani;Alessandro Rambaldi;Ercole Brusamolino

  • Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results

    Gianni Bonadonna;Pinuccia Valagussa;Armando Santoro

Frequent Co-Authors

Luca Gianni
Luca Gianni Vita-Salute San Raffaele University
Armando Santoro
Armando Santoro Humanitas University
Ana Lluch
Ana Lluch University of Valencia
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Umberto Veronesi
Umberto Veronesi European Institute of Oncology
Giuseppe Viale
Giuseppe Viale University of Milan
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Richard Gray
Richard Gray University of Oxford
Maria Grazia Daidone
Maria Grazia Daidone University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine or healthcare doesn’t always mean following a traditional path. Many students are now pursuing flexible programs to advance their skills and expertise. For those interested in food science and wellness, online nutrition degrees offer a specialized foundation in nutritional care—a growing area within healthcare.

Aspiring healthcare leaders can consider the best mha programs online, which focus on healthcare management and administration for broader career opportunities. Registered nurses (RN) seeking career growth may benefit from rn to bsn online no clinicals programs, which provide a convenient option to earn a bachelor’s degree without in-person clinicals.

For nurses aiming for the highest level of practice, fastest dnp online program options offer an accelerated route to a Doctor of Nursing Practice degree. These pathways are expanding access to advanced healthcare roles and responding to the demands of an evolving medical landscape.

Best Scientists Citing Pinuccia Valagussa

Trending Scientists

Recently Published Articles